Clofarabine Data Presented at European Hematology Association Meeting

Bioenvision has announced that results from clinical trials of clofarabine in adult AML were presented at the 10th European Hematology Association meeting in Stockholm, Sweden.

In the National Cancer Research Institute (NCRI), UK, multicenter study of older patients with AML who were unsuitable for intensive chemotherapy, the overall response for clofarabine was 67 percent.

Eleven (42 percent) patients in this trial had abnormal cytogenetics, and of these five (45 percent) achieved a complete response (CR) with clofarabine. For patients with "normal" cytogenetic profile, the CR was 73 percent. In addition, the median duration of remission in patients responding to clofarabine is currently 9.5+ months.